Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
暂无分享,去创建一个
R. Finkel | R. Petersen | B. Boeve | C. Ross | M. Grossman | A. Al-Chalabi | P. Andersen | R. Postuma | M. Benatar | H. Rosen | J. Wuu | M. Mcdermott | J. Rohrer | C. McMillan | J. Shefner | S. Abrahams | C. Stanislaw | Jalayne J Arias | V. Granit | S. Fradette | Caroline A. McHutchison | M. R. Turner | Stephanie Cosentino | Anne-Laure Grignon | Christine Stanislaw | M. Grossman | C. Mcmillan | Jalayne J. Arias
[1] R. Petersen. Aducanumab: What about the Patient? , 2021, Annals of neurology.
[2] G. Rabinovici. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab. , 2021, The New England journal of medicine.
[3] B. Dunn,et al. Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective. , 2021, JAMA internal medicine.
[4] R. Finkel,et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial , 2021, The Lancet Neurology.
[5] M. Mintun,et al. Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.
[6] J. V. van Swieten,et al. Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.
[7] D. Alexander,et al. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease , 2020, Science Translational Medicine.
[8] P. Svenningsson,et al. Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.
[9] A. Ludolph,et al. Cerebrospinal Fluid Levels of Prodynorphin‐Derived Peptides are Decreased in Huntington's Disease , 2020, Movement disorders : official journal of the Movement Disorder Society.
[10] Timothy A. Miller,et al. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. , 2020, The New England journal of medicine.
[11] B. Boeve,et al. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. , 2020, Annals of neurology.
[12] D. Burke,et al. A proposal for new diagnostic criteria for ALS , 2020, Clinical Neurophysiology.
[13] G. Frisoni,et al. Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers , 2020, Annals of neurology.
[14] Joey Tianyi Zhou,et al. A roadmap to using historical controls in clinical trials – by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG) , 2020, Orphanet Journal of Rare Diseases.
[15] Michael Wagner,et al. The characterisation of subjective cognitive decline , 2020, The Lancet Neurology.
[16] B. Boeve,et al. Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[17] David T. Jones,et al. Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study , 2019, Neurobiology of Aging.
[18] Nick C Fox,et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study , 2019, The Lancet Neurology.
[19] Nick C Fox,et al. Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study , 2019, The Lancet Neurology.
[20] David T. Jones,et al. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration , 2019, Alzheimer's & Dementia.
[21] D. Berg,et al. Parkinson disease genetics: too early to predict progression? , 2019, Nature Reviews Neurology.
[22] David T. Jones,et al. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology , 2019, Alzheimer's & Dementia.
[23] L. Servais,et al. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives , 2019, Therapeutics and clinical risk management.
[24] J. Mendell,et al. P.214Presymptomatic spinal muscular atrophy: reality or myth? , 2019, Neuromuscular Disorders.
[25] Sebastian Heinzel,et al. Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.
[26] R. Finkel,et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study , 2019, Neuromuscular Disorders.
[27] R. Reilmann,et al. Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories , 2019, Movement disorders clinical practice.
[28] P. Andersen,et al. Neurofilaments in pre-symptomatic ALS and the impact of genotype , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[29] David T. Jones,et al. Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers , 2019, Neurobiology of Aging.
[30] R. Petersen,et al. Data from: Subjective cognitive decline and risk of MCI: the Mayo Clinic Study of Aging , 2019 .
[31] W. M. van der Flier,et al. Added value of amyloid PET in individualized risk predictions for MCI patients , 2019, Alzheimer's & dementia.
[32] S. Fereshtehnejad,et al. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: a prospective study. , 2019, Brain : a journal of neurology.
[33] David T. Jones,et al. Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers , 2019, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[34] R. Barker,et al. Targeting Huntingtin Expression in Patients with Huntington's Disease. , 2019, The New England journal of medicine.
[35] Daniela Berg,et al. Prodromal Parkinson's Disease: The Decade Past, the Decade to Come , 2019, Movement disorders : official journal of the Movement Disorder Society.
[36] R. Finkel,et al. Neurofilament as a potential biomarker for spinal muscular atrophy , 2019, Annals of clinical and translational neurology.
[37] M. Benatar,et al. Defining pre-symptomatic amyotrophic lateral sclerosis , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[38] M. Ikram,et al. The incidence of mild cognitive impairment: A systematic review and data synthesis , 2019, Alzheimer's & Dementia.
[39] Veronica Redaelli,et al. Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study , 2019, Brain : a journal of neurology.
[40] Yves Dauvilliers,et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study , 2019, Brain : a journal of neurology.
[41] B. Miller,et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials , 2019, Brain : a journal of neurology.
[42] W. Jagust,et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes , 2019, Alzheimer's Research & Therapy.
[43] Nick C Fox,et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.
[44] David T. Jones,et al. Rates of lobar atrophy in asymptomatic MAPT mutation carriers , 2019, Alzheimer's & Dementia.
[45] D. Alexander,et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease , 2018, Science Translational Medicine.
[46] R. Petersen. How early can we diagnose Alzheimer disease (and is it sufficient)? , 2018, Neurology.
[47] Jung-Han Kim,et al. Stereotactic Core-Needle Biopsy of Non-Mass Calcifications: Outcome and Accuracy at Long-Term Follow-Up , 2003, Korean journal of radiology.
[48] Phil Woodward,et al. Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities , 2018, Therapeutic innovation & regulatory science.
[49] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[50] David T. Jones,et al. In vivo 18F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms , 2018, Neurology.
[51] R. Finkel,et al. Nusinersen versus Sham Control in Later‐Onset Spinal Muscular Atrophy , 2018, The New England journal of medicine.
[52] Ronald C. Petersen,et al. Practice guideline update summary: Mild cognitive impairment , 2018, Neurology.
[53] A. Al-Chalabi,et al. ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen , 2018, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[54] Hiroko H. Dodge,et al. Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in the Uniform Data Set (UDS) , 2017, Alzheimer disease and associated disorders.
[55] R. J. Ramamurthi,et al. Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[56] Brian K. Kaspar,et al. Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[57] K. Blennow,et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis , 2017, The Lancet Neurology.
[58] D. Jennings,et al. Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter–Deficit Prodromal Cohort , 2017, JAMA neurology.
[59] C. Smart,et al. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. , 2017, Annual review of clinical psychology.
[60] K. Blennow,et al. Tau or neurofilament light—Which is the more suitable biomarker for Huntington’s disease? , 2017, PloS one.
[61] R. Freeman,et al. Natural history of pure autonomic failure: A United States prospective cohort , 2017, Annals of neurology.
[62] T. Hortobágyi,et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[63] O. Hardiman,et al. Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI) , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[64] Chengjie Xiong,et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.
[65] Knut Engedal,et al. Frontotemporal Dementia , 2016, Journal of geriatric psychiatry and neurology.
[66] Keith A. Johnson,et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.
[67] P. Andersen,et al. Presymptomatic ALS genetic counseling and testing , 2016, Neurology.
[68] C. Broeckhoven,et al. Molecular genetics of early-onset Alzheimer's disease revisited , 2016, Alzheimer's & Dementia.
[69] Eric E. Smith,et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment , 2016, Alzheimer's & Dementia.
[70] Günther Deuschl,et al. MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[71] Lee Ashendorf,et al. Reliable Change on Neuropsychological Tests in the Uniform Data Set , 2015, Journal of the International Neuropsychological Society.
[72] Jane S. Paulsen,et al. Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease , 2015, Cell.
[73] M. Hayden,et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression , 2015, Scientific Reports.
[74] S. Tabrizi,et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. , 2015, The Journal of clinical investigation.
[75] S. Chandran,et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders , 2015, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[76] Veronica Redaelli,et al. Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis , 2015, The Lancet Neurology.
[77] Jane S. Paulsen,et al. Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study , 2014, The Lancet Neurology.
[78] N. Jetté,et al. The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[79] Andrew J. Saykin,et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease , 2014, Alzheimer's & Dementia.
[80] E. Aylward. Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[81] Keith A. Johnson,et al. Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants , 2014, Alzheimer's Research & Therapy.
[82] Jane S. Paulsen,et al. Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.
[83] J. Karlawish,et al. The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.
[84] G. Deuschl,et al. Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease , 2014, Movement disorders : official journal of the Movement Disorder Society.
[85] Elaine Niven,et al. Screening for cognition and behaviour changes in ALS , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.
[86] Chris Frost,et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.
[87] R. Finkel. Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I , 2013, Neuromuscular Disorders.
[88] W. Poewe,et al. The PRIPS study: screening battery for subjects at risk for Parkinson's disease , 2013, European journal of neurology.
[89] B. Berkman,et al. When Does an Illness Begin: Genetic Discrimination and Disease Manifestation , 2012, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.
[90] I. Mackenzie,et al. Advances in understanding the molecular basis of frontotemporal dementia , 2012, Nature Reviews Neurology.
[91] Christopher A. Ross,et al. Striatal Volume Contributes to the Prediction of Onset of Huntington Disease in Incident Cases , 2012, Biological Psychiatry.
[92] K. Duff. Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. , 2012, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[93] Jane S. Paulsen,et al. Indexing disease progression at study entry with individuals at‐risk for Huntington disease , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[94] S. Bruley des Varannes,et al. Parkinson disease , 2011, Neurology.
[95] Ranjan Duara,et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. , 2011, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[96] 김태희,et al. Wisconsin Card Sorting Test-64 Card Version(WCST-64)의 한국 노인 정상규준 연구 , 2011 .
[97] Nick C Fox,et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.
[98] H. Zetterberg,et al. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson’s disease , 2011, Acta neurologica Scandinavica.
[99] T. Gollan,et al. Self-ratings of spoken language dominance: A Multilingual Naming Test (MINT) and preliminary norms for young and aging Spanish–English bilinguals* , 2011, Bilingualism: Language and Cognition.
[100] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.
[101] R. Petersen. Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.
[102] P. Andersen,et al. Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis , 2011, Genetics in Medicine.
[103] B. Miller,et al. Classification of primary progressive aphasia and its variants , 2011, Neurology.
[104] Chris Frost,et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis , 2011, The Lancet Neurology.
[105] Bruce L. Miller,et al. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia , 2011, Neuropsychologia.
[106] Jane S. Paulsen,et al. CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[107] R. D. de Haan,et al. The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[108] M. York,et al. Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS™) , 2010, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[109] 寺田 達弘,et al. Frontal Systems Behavior Scale (FrSBe) , 2009 .
[110] Jane S. Paulsen,et al. Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study , 2009, Movement disorders : official journal of the Movement Disorder Society.
[111] Nick C Fox,et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data , 2009, The Lancet Neurology.
[112] M. Freedman,et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[113] Roger A. Barker,et al. The Cambridge Behavioural Inventory revised , 2008, Dementia & neuropsychologia.
[114] Jane S. Paulsen,et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[115] M. Benatar,et al. Diagnostic Accuracy of Thoracic Paraspinal Electromyography in Amyotrophic Lateral Sclerosis , 2007, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[116] M. Benatar,et al. The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria? , 2007, Muscle & nerve.
[117] S. Tabrizi,et al. Predict-HD and the future of therapeutic trials , 2006, The Lancet Neurology.
[118] Jane S. Paulsen,et al. Preparing for preventive clinical trials: the Predict-HD study. , 2006, Archives of neurology.
[119] Mark B Bromberg,et al. Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function , 2005, Annals of neurology.
[120] R. Petersen. Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.
[121] B. Miller,et al. Are amyotrophic lateral sclerosis patients cognitively normal? , 2003, Neurology.
[122] T. Wienker,et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.
[123] Michael J. Taylor,et al. Sensitivity and specificity of WAIS–III/WMS–III demographically corrected factor scores in neuropsychological assessment , 2001, Journal of the International Neuropsychological Society.
[124] S. Baron-Cohen,et al. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. , 2001, Journal of child psychology and psychiatry, and allied disciplines.
[125] E. Kaplan,et al. The Boston naming test , 2001 .
[126] L. Goldstein,et al. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS) , 2000, Neuropsychologia.
[127] Arnold Munnich,et al. Correlation between severity and SMN protein level in spinal muscular atrophy , 1997, Nature Genetics.
[128] M. MacDonald,et al. CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.
[129] A. Kertesz,et al. Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementi , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[130] K. Zerres,et al. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. , 1995, Archives of neurology.
[131] G. Chelune,et al. 'T scores for change': An illustration of a regression approach to depicting change in clinical neuropsychology , 1993 .
[132] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[133] N. Jacobson,et al. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. , 1991, Journal of consulting and clinical psychology.
[134] O. Spreen,et al. Predicting premorbid IQ: A revision of the national adult reading test , 1989 .
[135] Cecil R. Reynolds,et al. A demographically based index of premorbid intelligence for the WAIS—R. , 1984 .
[136] A. Benton,et al. Visuospatial judgment. A clinical test. , 1978, Archives of neurology.
[137] S J Pocock,et al. The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.
[138] Jane S. Paulsen,et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. , 2016, JAMA neurology.
[139] Fang Chen,et al. Use of historical control data for assessing treatment effects in clinical trials , 2014, Pharmaceutical statistics.
[140] T. Schneid,et al. The Genetic Information Nondiscrimination Act of 2008 (GINA) , 2011 .
[141] N. Talley. Medical records documentation of constipation preceding Parkinson disease: A case-control study , 2010 .
[142] S. Hersch. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. , 2006, Archives of neurology.
[143] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.